University Hospital of Geneva-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2020

  1. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon

    The Lancet HIV, Vol. 7, Núm. 10, pp. e677-e687